Literature DB >> 31335353

Tumor Budding in Intrahepatic Cholangiocarcinoma: A Predictor of Postsurgery Outcomes.

Mariko Tanaka1, Naoko Yamauchi1, Tetsuo Ushiku1, Junji Shibahara1, Akimasa Hayashi1, Kento Misumi1, Yoichi Yasunaga1, Teppei Morikawa2, Takashi Kokudo3, Junichi Arita3, Yoshihiro Sakamoto4, Kiyoshi Hasegawa3, Masashi Fukayama1.   

Abstract

Intrahepatic cholangiocarcinoma (ICC) is an extremely aggressive carcinoma. Useful predictors for the patients' prognosis after surgery have not been fully established. From the University of Tokyo Hospital pathology archives, we reviewed 107 cases of ICC, 54 cases of perihilar cholangiocarcinoma, and 40 cases of extrahepatic cholangiocarcinoma (ECC); we also investigated the significance of tumor budding in ICC, in comparison with perihilar cholangiocarcinoma and ECC. The tumor-budding frequencies were different by tumor location: 40.2% (43/107) in ICC, 70.4% (38/54) in perihilar cholangiocarcinoma, and 60.0% (24/40) in ECC. Tumor budding in ICC was associated with many pathologic indicators associated with invasion, such as major vascular invasion (P=0.012) and Union for International Cancer Control stage (P=0.007). Univariate and multivariate Cox regression analyses revealed tumor budding as a powerful prognostic factor for both recurrence-free survival (RFS) and overall survival (OS) in ICC by univariate (RFS: hazard ratio [HR]: 2.666; 95% confidence interval [CI]: 1.517-4.683, OS: HR: 4.206; 95% CI: 2.447-7.230) and by multivariate analyses (RFS: HR: 3.038; 95% CI: 1.591-5.973, OS: HR: 4.547, 95% CI: 2.348-8.805). Tumor budding was also a significant prognostic factor of perihilar cholangiocarcinoma, but not of ECC. When ICC was divided into 2 subtypes, type 1 (hilar) and type 2 (peripheral), tumor budding was the strong prognostic factor in type 2 ICC, but not in type 1 ICC, suggesting that some differences in biological behavior exist between type 1 ICC and perihilar cholangiocarcinoma. Tumor budding is prognostically important in ICC, and its pathogenetic role in biliary tract carcinomas might be different by anatomic location.

Entities:  

Mesh:

Year:  2019        PMID: 31335353     DOI: 10.1097/PAS.0000000000001332

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

Review 1.  Tumour budding in solid cancers.

Authors:  Alessandro Lugli; Inti Zlobec; Martin D Berger; Richard Kirsch; Iris D Nagtegaal
Journal:  Nat Rev Clin Oncol       Date:  2020-09-08       Impact factor: 66.675

2.  High tumor budding predicts a poor prognosis in resected duodenal adenocarcinoma.

Authors:  Tatsuma Sakaguchi; Sohei Satoi; Daisuke Hashimoto; Tomohisa Yamamoto; So Yamaki; Satoshi Hirooka; Mitsuaki Ishida; Tsukasa Ikeura; Kentaro Inoue; Makoto Naganuma; Hideki Ishikawa; Mitsugu Sekimoto
Journal:  Surg Today       Date:  2022-01-06       Impact factor: 2.549

3.  Prognostic Impact of Tumor Budding in Intrahepatic Cholangiocellular Carcinoma.

Authors:  Klara-Luisa Budau; Carlie S Sigel; Luise Bergmann; Anne-Marie Lüchtenborg; Ulrich Wellner; Oliver Schilling; Martin Werner; Laura Tang; Peter Bronsert
Journal:  J Cancer       Date:  2022-05-06       Impact factor: 4.478

4.  Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection.

Authors:  Wei-Feng Qu; Pei-Yun Zhou; Wei-Ren Liu; Meng-Xin Tian; Lei Jin; Xi-Fei Jiang; Han Wang; Chen-Yang Tao; Yuan Fang; Yu-Fu Zhou; Shu-Shu Song; Zhen-Bin Ding; Yuan-Fei Peng; Zhi Dai; Shuang-Jian Qiu; Jian Zhou; Jia Fan; Zheng Tang; Ying-Hong Shi
Journal:  Ann Transl Med       Date:  2020-04

Review 5.  Tumour budding and its clinical implications in gastrointestinal cancers.

Authors:  Inti Zlobec; Martin D Berger; Alessandro Lugli
Journal:  Br J Cancer       Date:  2020-06-30       Impact factor: 7.640

6.  Tumor Budding Score Is a Strong and Independent Prognostic Factor in Patients With Pancreatic Ductal Adenocarcinoma: An Evaluation of Whole Slide Pathology Images of Large Sections.

Authors:  Hui Jiang; Yelin Yang; Yuping Qian; Chengwei Shao; Jianping Lu; Yun Bian; Jianming Zheng
Journal:  Front Oncol       Date:  2021-11-30       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.